Business Wire

German Diabetes Clinic Increases Diabetic Retinopathy Screenings From Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System

Share

Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion into Germany. Since adopting the EyeArt AI Eye Screening System in October 2018, Diabetes Center Mergentheim has screened thousands of diabetic patients, identifying approximately 10% with cases of referable diabetic retinopathy (DR). The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults.1

The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible for any physician, enabling quick and accurate identification of patients with referable DR during a diabetic patient’s regular physician visit. Once the patient’s fundus images have been captured and submitted to the EyeArt System, the DR screening results are available to view and export to a PDF report in less than 60 seconds. The EyeArt System can free eye care specialists to focus on sight-saving treatment rather than screening for DR.

At Diabetes Center Mergentheim, more than 20,000 patients with diabetes are seen each year by diabetes care specialists. Before adopting the EyeArt System, patients would be referred to ophthalmologists outside of the clinic. This process placed undue burden on patients, and often they would never get the necessary screening.

“EyeArt AI Eye Screening System is helping us improve diabetic patient care. We can now offer eye screening right in our clinic, without dilation, while reducing wait time for screening and results,” said Prof. Dr. med. Thomas Haak, head physician of Diabetes Center Mergentheim and founding member and board director of DiabetesDE. “The accuracy and convenience of the EyeArt System is allowing us to identify and treat DR effectively and quickly. The patients with no referable DR feel good that they can be screened again in a year, and the patients with identified referable DR can feel good that their silently progressing retinopathy has been identified and will be treated before any loss of sight.”

About 7.5 million people in Germany have diabetes mellitus2, with over 2,500 patients going blind due to diabetic retinopathy each year. German guidelines recommend at-risk patients be screened annually, but this can be difficult with the shortage of eye doctors. By incorporating the EyeArt System into their clinic, Diabetes Center Mergentheim has addressed a serious complication associated with diabetes — the center now screens 10 to 15 patients per day for this vision-threatening condition.

“Last year, we began our partnership with Diabetes Center Mergentheim with a great promise, and now it is very gratifying to see the promise turning into real meaningful impact that EyeArt System’s adoption is making to the diabetes patients in the Bad Mergentheim community,” said Kaushal Solanki, founder and CEO of Eyenuk. “We are now replicating our success to clinics throughout Germany, taking us one more step further in realizing our mission to screen every eye in the world.”

About Diabetic Retinopathy (DR)

DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease that at first may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The condition can develop in anyone who has type 1 or type 2 diabetes.3 It is estimated that one-third of all patients with diabetes will develop DR,4 making it the leading cause of vision loss in working-age adults.5

While DR screening is recommended for all diabetic patients, less than half get screened annually1, even in the developed world. Since diabetic patients outnumber ophthalmologists by 1,130 to 1 in Germany6, there are just not enough eye care specialists to meet the DR screening needs of the growing diabetic population. Even for those receiving an annual screening, ophthalmology appointment wait times for DR screening can be weeks or even months.

About the EyeArt AI Eye Screening System

The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of DR, tested in the real world on more than a half million patient visits globally with over 2 million images collected in real-world clinical environments. The EyeArt System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). The EyeArt System has CE marking in the European Union and a Health Canada license. In the U.S., the EyeArt System is limited by federal law to investigational use.

VIDEO: Learn more about the EyeArt AI Eye Screening System for Diabetic Retinopathy at the Diabetes Center Mergentheim

About Eyenuk Inc.

Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.

EyeArt is a registered trademark of Eyenuk Inc.

www.eyenuk.com

____________________

1   Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603
2

International Diabetes Federation (2017) IDF Diabetes Atlas, 8th edn. http://www.idf.org/diabetesatlas

3

https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611

4 Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909
5 Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603
6

http://www.icoph.org/ophthalmologists-worldwide.html

Contact information

Media Contact:
Capwell Communications
Ida Yenney
ida@capwellcomm.com
949-999-3303

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Delta-Q Technologies Announces Its New RQ350 Battery Charger for Electric Vehicles and Machines27.5.2020 23:51:00 EESTPress release

Today, Delta-Q Technologies (Delta-Q) introduces its latest sealed charger with the RQ350 for electric vehicles and industrial machines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005918/en/ The RQ350 is an expansion of Delta-Q's RQ Series offering OEMs a charging solution for lower power applications. (Photo: Business Wire) Having found significant market success with the IC Series chargers rated from 650 to 1200 watts, Delta-Q has set its sights on lower power applications with its new 350-watt charger. This new build was designed and tested to meet automotive levels of product reliability, improving machine runtimes. “The RQ350 is a response to our customers’ needs in multiple application segments,” says Lloyd Gomm, VP of Business Development. “Our customers have asked us to bring our high reliability charger design into both lower and higher capacity battery charging applications. The RQ350 solidly answers the

City of Austin Partners with NTT to Accelerate Smart City Technologies27.5.2020 23:00:00 EESTPress release

The City of Austin and NTT Corporation (NTT) today announced their intention to partner on an Accelerate Smart pilot project that will use new technologies to analyze traffic patterns, ease congestion and support community planning in Austin. NTT’s Accelerate Smart data platform, as well as modular data center infrastructure for edge deployments, will monitor traffic-related issues downtown using Internet of Things (IoT) devices deployed at the intersections of Cesar Chavez Street and Trinity Street and Neches Street and 8th Street. The smart city project will collect traffic-related and mobility data through vehicle counting and classification, as well as wrong way vehicle occurrences, to provide real-time notifications and better inform how to implement appropriate solutions to fit traffic patterns. “We are piloting NTT because these solutions have the potential to help Austin digitally transform how people move safely through the city. By better understanding the data and causal eff

Monument Re Completes Acquisition of GreyCastle Holdings Ltd and Its Subsidiaries27.5.2020 20:54:00 EESTPress release

Monument Re announced today that it has completed the acquisition of GreyCastle Holdings Ltd. (‘GreyCastle’) and its subsidiaries, which include GreyCastle Life Reinsurance (SAC) Ltd. and GreyCastle Services Ltd., following receipt of regulatory approval from the Bermuda Monetary Authority. About GreyCastle GreyCastle was founded in 2014 by a group of institutional investors to reinsure a block of XL Life Reinsurance life and annuity liabilities of approximately USD4bn. About Monument Re Monument Re Limited is a life Reinsurance and Insurance Holding Company with a presence in Bermuda, Ireland, Belgium, Luxembourg, the Netherlands and Guernsey, with branches in Spain, Italy, France and Germany. Monument Re operates as a reinsurer and acquirer of European asset intensive portfolios. Through this strategy, Monument Re assumes asset-based risks within its risk appetite and efficiently operates these businesses or portfolios. Monument Re is subject to Group Supervision by the Bermuda Monet

Morgan Stanley Sustainable Signals: Asset Owners See Sustainability as Core to Future of Investing27.5.2020 16:18:00 EESTPress release

A majority of asset owners globally actively integrate ESG factors into their investment process, according to a new survey published today by the Morgan Stanley Institute for Sustainable Investing and Morgan Stanley Investment Management. The new survey polled 110 public and corporate pensions, endowments, foundations, sovereign wealth entities, insurance companies and other large asset owners worldwide, 92% of which had total assets over $1 billion. The survey gathered insights about trends, motivations, challenges and implementation approaches in sustainable investing. This work builds on the Institute’s extensive body of research tracking sustainable investing trends over the last six years through its Sustainable Signals survey series focused on individual investors, asset owners and asset managers. “These results provide an additional proof point that sustainable investing has become table stakes,” said Audrey Choi, Chief Sustainability Officer and CEO of the Institute for Sustai

Sisvel Announces the First Licensees of Its Video Coding Licensing Platform27.5.2020 16:00:00 EESTPress release

Sisvel International S.A. (“Sisvel”) today announced that Mitsubishi Electric Corporation (“Mitsubishi Electric”) has entered into a patent license agreement for both Sisvel’s VP9 and AV1 Licensing Programs. “As a company with a long tradition in research and development in the video coding technologies, it goes without saying that we respect patent positions held by other innovators and that we take a license under the patents offered by Sisvel’s Video Coding Licensing Platform implemented in our products,” says Mr. Yoshimichi Shishido, Senior General manager of Corporate Licensing Division at Mitsubishi Electric. “We have the utmost respect for Mitsubishi Electric’s position and welcome them as the first licensee of our patent pools. We believe this represents a strong signal to the market and we expect that other respectful implementers will follow Mitsubishi Electric’s example,” says Mattia Fogliacco, President of Sisvel International S.A.. Likewise, Sisvel has also granted a licen

Rimini Street Speeds Software Issue Resolution by 23% with New Artificial Intelligence Applications27.5.2020 16:00:00 EESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has reduced software issue resolution times by 23% using its new patent pending Rimini Street Artificial Intelligence Support Applications (AI Applications), and that to date the AI Applications have won two awards for innovation and achievement in customer service. The new AI Applications are a result of Rimini Street’s continued investment in optimizing support processes and ensuring global service delivery outcomes at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005073/en/ Rimini Street Speeds Software Issue Resolution by 23% with New Artificial Intelligence Applications (Graphic: Business Wire) Delivering a Better Client Experience Through Artificial Intelligence The Rimini Street A

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom